ViGenCell Inc. (KOSDAQ:308080)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,990.00
-530.00 (-9.60%)
At close: Apr 2, 2026
Market Cap103.73B +88.6%
Revenue (ttm)278.95M
Net Income-12.56B
EPS-650.72
Shares Out20.50M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume498,076
Average Volume424,185
Open5,500.00
Previous Close5,520.00
Day's Range4,870.00 - 5,540.00
52-Week Range2,755.00 - 17,360.00
Beta0.72
RSI38.97
Earnings Daten/a

About ViGenCell

ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic universal T cell gene therapy comprising VR-CAR and VR-GDT for hepatoma and leukemia indications. The company was founded in 2013 and is based in Seoul, Sou... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2013
Employees 64
Stock Exchange KOSDAQ
Ticker Symbol 308080
Full Company Profile

Financial Performance

Financial Statements